Bullish indicating open at $55-$60, IPO prices at $37
Oleg Movchan, the Chief Executive Officer of Enfusion , Inc. (NYSE:ENFN), a fintech company with a market capitalization of $1.47 billion and impressive revenue growth of 15.5% over the last twelve months, has recently sold a portion of his holdings in the company. The stock has shown strong momentum, gaining over 41% in the past six months and currently trading near its 52-week high of $11.80. According to a recent SEC filing, Movchan disposed of 2,790 shares of Class A Common Stock on March 3, 2025, with the shares sold at a weighted average price of $11.481, ranging between $11.429 and $11.535. The total value of the transaction amounted to $32,031.
The sale was executed by CSL (OTC:CSLLY) Tech Holdings LLC, where Movchan holds a managerial position. Following this transaction, Movchan’s indirect ownership stands at 1,151,818 shares, held by CSL Tech Holdings. The shares sold were required to cover tax withholding obligations, as noted in the filing, and do not represent discretionary trades by Movchan.
In other recent news, Enfusion Inc has announced its fourth-quarter earnings for 2024, coinciding with a significant development regarding its acquisition by Clearwater Analytics. The acquisition agreement sets the share price at $11.25, a figure that has become a benchmark for analysts and investors. Following this announcement, Stifel downgraded Enfusion’s stock from Buy to Hold and adjusted its price target to align with the acquisition price, citing the agreement as a favorable outcome for shareholders. Similarly, Morgan Stanley (NYSE:MS) downgraded the stock from Overweight to Equal-weight while increasing the price target to $11.25, matching the acquisition offer.
The acquisition is seen as a strategic move to expedite value realization for Enfusion’s shareholders and address past concerns regarding its market position. Analysts at Morgan Stanley noted that Enfusion’s performance had been on the lower end of projections, adding context to the acquisition’s perceived benefits. The acquisition price represents a 13% premium over the stock’s previous closing price, reflecting Clearwater’s commitment to the deal.
Stifel’s analysts have expressed confidence in the acquisition’s terms, suggesting limited chances for a competing bid. This development indicates a significant transition for Enfusion, with market expectations now focused on the completion of the acquisition. Investors are closely monitoring these changes as the situation unfolds.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.